Shahidi Neal, Bressler Brian, Panaccione Remo
a Division of Gastroenterology, Department of Medicine , University of British Columbia , Vancouver , BC , Canada.
b Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology , University of Calgary , Rm 6D32, TRW Building, 3280 Hospital Drive Northwest, Calgary , AB , Canada T2N 4N1.
Expert Opin Biol Ther. 2016;16(1):129-35. doi: 10.1517/14712598.2016.1121231. Epub 2015 Dec 9.
With a need for a larger armamentarium of therapeutic options for those suffering from moderate-to-severe ulcerative colitis, vedolizumab, an α4β7-integrin biologic therapy, has recently received approval in the United States, Canada and Europe. However, it is unclear where it should be positioned in relation to current therapies for moderate-to-severe ulcerative colitis.
We systematically reviewed the literature for phase 1, phase 2 and phase 3 randomized controlled trials assessing the role of vedolizumab in ulcerative colitis.
Trials assessing vedolizumab highlight its arrival as an effective and safe therapy for patients suffering from ulcerative colitis.
对于中重度溃疡性结肠炎患者而言，需要更多的治疗选择，α4β7整合素生物疗法维多珠单抗最近在美国、加拿大和欧洲获得批准。然而，与目前中重度溃疡性结肠炎的治疗方法相比，其应处于何种地位尚不清楚。
我们系统回顾了评估维多珠单抗在溃疡性结肠炎中作用的1期、2期和3期随机对照试验的文献。
评估维多珠单抗的试验表明，它已成为治疗溃疡性结肠炎患者的一种有效且安全的疗法。
